Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women
- 1 May 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Menopause
- Vol. 14 (3), 391-396
- https://doi.org/10.1097/01.gme.0000236939.81819.6c
Abstract
Women with higher mammographic breast density have increased risk for breast cancer, and there is some evidence that a change in breast density may be a marker for change in risk for breast cancer. The purpose of this study was to determine whether 2 years of treatment with ultra-low-dose transdermal estradiol results in a change in breast density. The Ultra-Low-dose Transdermal Estradiol Assessment was a randomized, blinded, placebo-controlled trial of 2 years of treatment with unopposed ultra-low-dose (0.014 mg/d) transdermal estradiol for prevention of osteoporosis in 417 postmenopausal women with no history of breast cancer who had not had a hysterectomy. We obtained mammograms at baseline and after 1 and 2 years of treatment from 276 of the participants. Right craniocaudal views were analyzed at a central radiology facility by a trained clinician blinded to treatment group and order of acquisition. Contour analysis was performed to define dense areas versus fatty tissue. Between-group differences in mean change in percent breast density from baseline to 1 and to 2 years of follow-up were assessed using linear regression models adjusted for clinical site. Participants were 66 +/- 5 years old and 94% were white. The average percent breast density at baseline was 34%. There was no significant difference between treatment groups in change in percent breast density after 1 year (between-group difference, 0.1%; 95% confidence interval, -1.3% to 1.6%) or 2 years of treatment (0.8%; -0.6% to 2.1%). Two years of treatment with ultra-low-dose transdermal estradiol did not increase breast density.Keywords
This publication has 19 references indexed in Scilit:
- Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women's Health Initiative Randomized TrialJNCI Journal of the National Cancer Institute, 2005
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Quantitative Assessment of Mammographic Breast Density: Relationship with Breast Cancer RiskRadiology, 2004
- Postmenopausal Hormone Therapy and Change in Mammographic DensityJNCI Journal of the National Cancer Institute, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- The association of increased weight, body mass index, and tissue density with the risk of breast carcinoma in VermontCancer, 2000
- Effects of Estrogen and Estrogen–Progestin on Mammographic Parenchymal DensityAnnals of Internal Medicine, 1999
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- Mammographic Features and Breast Cancer Risk: Effects With Time, Age, and Menopause StatusJNCI Journal of the National Cancer Institute, 1995
- Quantitative Classification of Mammographic Densities and Breast Cancer Risk: Results From the Canadian National Breast Screening StudyJNCI Journal of the National Cancer Institute, 1995